Compare Domino's Pizza, Inc. (DPZ) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Domino's Pizza, Inc. vs Natera Inc. Common Stock — how do they compare? Domino's Pizza, Inc. trades at $294.5 (market cap $9.74B), while Natera Inc. Common Stock trades at $394 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 5.9× Domino's Pizza, Inc.'s market cap, and Domino's Pizza, Inc. pays a 2.69% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Domino's Pizza, Inc. for 106 Days and Natera Inc. Common Stock for 0 Days on average.
| DPZ | NTRA | |
|---|---|---|
Market Cap | $9.74B | $57.03B |
Volume | 2,053,142 | 1,131,157 |
Sector | Consumer Cyclical | Health |
52-Week High | $438.42 | $425.64 |
52-Week Low | $282.89 | $179.42 |
Typical Hold Time | 106 Days | 0 Days |
Enterprise Value | $14.63B | $56.18B |
Dividend Yield | 2.69% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Domino's Pizza (DPZ) trades at $295.89, down 4.83% with mixed technical signals but strong fundamentals. The stock shows a bullish overall technical signal despite recent price weakness, while fundamentals reveal consistent revenue growth to $4.94 billion in 2025 and healthy net margins of 11.86%. Recent earnings show improvement with a Q3 2026 beat after three consecutive misses, though the company faces high debt levels and flat dividend growth.
The outlook remains cautiously optimistic with a $368 consensus price target representing 24% upside potential. Key opportunities include sustained profitability and market leadership, while risks center on high leverage and competitive pressures. Analyst sentiment leans bullish with 50% buy ratings, but investors should monitor debt management and same-store sales trends.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Domino's Pizza, Inc.
Domino's is a restaurant operator and franchiser with nearly 19,000 global stores across more than 90 international markets at the end of 2021. The firm generates revenue through the sales of pizza, wings, salads, and sandwiches at company-owned stores, royalty and marketing contributions from franchise-operated stores, and its network of 25 domestic (and five Canadian) dough manufacturing and supply chain facilities, which centralize purchasing, preparation, and last-mile delivery for the firm's U.S. and Canadian restaurants. With roughly $17.7 billion in 2021 system sales, Domino's is the largest player in the global pizza market, ahead of Pizza Hut, Papa John's, and Little Caesars.
Read more on DPZ →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
